1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Alnylam Onpattro’s Expanded Use Gets Weak Thumbs Up From US FDA Panel

 
• By Sarah Karlin-Smith

A restrictive label could be the result of the lukewarm endorsement from the majority of the agency’s Cardiovascular and Renal Drugs Advisory Committee for use of Onpattro for the treatment of ATTR-associated cardiomyopathy.

baseball player bunting
Two FDA advisors described Alnylam’s Onpattro ATTR cardiomyopathy data as a 'bunt single' in lukewarm positive panel. • Source: Shutterstock

US Food and Drug Administration advisors voted 9-3 that the benefits of Alnylam Pharmaceuticals Inc.’s Onpattro outweigh its risk for the treatment of ATTR-associated cardiomyopathy, but the seemingly lopsided vote was not overly enthusiastic and may suggest the drug is headed for a limited use label or perhaps still the complete response letter FDA seemed like it might have been leaning towards going into the 13 September meeting.

Alnylam is seeking a supplemental indication for Onpattro (patisiran) for the treatment of cardiomyopathy of wild type or inherited transthyretin amyloidosis (ATTR)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet

 
• By Bridget Silverman

The 31 May goal date for Moderna’s next-generation COVID-19 vaccine looms over the month, but the US FDA's decision lineup includes three more novel agents, including AbbVie's Teliso-V antibody-drug conjugate, as well as supplemental indications like GSK's bid for Nucala in COPD.

AMR-Targeting Drug Secures EMA PRIME Designation

 
• By Neena Brizmohun

Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.

US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman

Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.

‘Pipeline In A Pill’ Or Pipe Dream? US FDA’s April Goal Dates Test Expansion Strategies

 
• By Bridget Silverman

Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.

More from Regulatory Trackers